Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020

1
Colorectal Cancer Therapeutics in Asia-Pacific
Markets to 2020-Improved Regional Healthcare
Access to Drive Uptake of High-Cost Targeted
Therapies
2
Report Overview
 
GBI Research, the leading business intelligence
provider, has released its latest research,
"Colorectal Cancer Therapeutics in Asia-Pacific
Markets to 2020 Improved Regional Healthcare
Access to Drive Uptake of High-Cost Targeted
Therapies", which provides in-depth insights into
the indication. It gives an estimation of market
size for 2013 along with forecasts until 2020 for
the Asia-Pacific (APAC) region, which comprises
Australia, China, India and Japan. It also
covers disease epidemiology, treatment
algorithms, treatment patterns, in-depth analysis
of clinical trials including failure rates and
pipeline analysis, and analysis of deals relevant
to Colorectal Cancer (CRC). The market in the
APAC region was worth an estimated 1.9 billion
in 2013 and is expected to grow at a Compound
Annual Growth Rate (CAGR) of 6.5 to 1.9 billion
in 2020. The use of targeted therapies is
expected to increase in the Asia-Pacific (APAC)
markets (for the purposes of this report, APAC
refers to Australia, China, India and Japan
only), as patient access to these more expensive
agents improves.
3
Report Overview
 
The moderate uptake of late-stage pipeline
products panitumumab and Xilonix, following their
expected approval, is expected to drive
additional growth within this market. Others such
as ramucirumab, TAS-102, TS-1, MelCancerVac will
also contribute. An increasingly aging population
and a year-on-year increase in the number of
incident cases will provide an additional boost.
However, the recent implementation of a price
ceiling on essential drugs in India anticipated
pricing restrictions in China and low access,
penetration and price erosion due to generic
dominance, especially in India, stand to curtail
the APAC CRC market. Get more about this report
at http//www.bigmarketresearch.com/colorectal-ca
ncer-therapeutics-in-asia-pacific-to-2020-improved
-regional-healthcare-access-to-drive-uptake-of-hig
h-cost-targeted-therapies-market
4
Scope

• The report analyzes treatment usage patterns,
  market characterization, the pipeline, and key
  licensing and co-development deals in the four
  APAC markets of Australia, China, India and
  Japan. It includes
• A brief introduction to CRC, including the
  diseases pathogenesis, etiology, diagnosis and
  treatment algorithms
• In-depth analysis of currently marketed drugs for
  CRC, examining their safety, efficacy, treatment
  patterns and strengths/weaknesses and including a
  heat map that compares the drugs in terms of
  safety and efficacy
• A comprehensive review of the pipeline for CRC,
  including individual analysis of a number of
  late-stage pipeline drugs that are likely to
  enter the market during the forecast period the
  pipeline is analyzed on the basis of Phase
  distribution, molecule type, program type,
  mechanism of action and molecular target
• Additional in-depth analysis of pipeline drug
  clinical trials by Phase, trial size, trial
  duration and program failure rate for each
  molecule type

5
Scope

• Multi-scenario forecast data of the market to
  2020, taking into account how the market may be
  affected by the introduction of new drugs, the
  expiry of key patents on current drugs and the
  changes in disease epidemiology across the key
  developed markets
• Discussion of the drivers of and barriers to
  market growth
• In-depth analysis of all licensing and
  co-development deals that have occurred in the
  CRC market since 2006
•  
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/176581

6
Table Of Content
1 Table of Contents 2 Introduction 8 3
Marketed Products 20 4 Pipeline Analysis 31 5
Market Forecast to 2020 47 6 Deals and Strategic
Consolidations 63 7 Appendix 68
7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/colorectal-cancer
-therapeutics-in-asia-pacific-to-2020-improved-reg
ional-healthcare-access-to-drive-uptake-of-high-co
st-targeted-therapies-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
sales_at_bigmarketresearch.com